November 8, 2012 - CML - Diagnosis and Treatment Update
- CML treatment options in an era of multiple approved oral therapy drugs
- Discussion points between patients and their healthcare teams to help with treatment decisions
- The importance of monitoring treatment response and follow-up screenings
- Psychosocial aspects of living with a chronic cancer
- Resources to help patients manage the impact of costs associated with CML treatment
Neil P. Shah, MD, PhD
Associate Professor in Residence
Edward S. Ageno Distinguished Professor of Hematology/Oncology
Leader, Hematopoietic Malignancies Program
Helen Diller Family Comprehensive Cancer Center at University of California at San Francisco
San Francisco, CA
Questions Asked by the CML Community
- What have the long-term responses been of people who stop taking any oral medication (tyrosine kinase inhibitors)?
- For a patient who has had a 3 log reduction, is it possible, at any point, to go into remission?
- In a study mentioned in this program, why did 45% of study patients, who are no longer on imatinib, leave the program? Did they stop taking Gleevec or did they leave for medical reasons?
- Should a patient try a new drug if side effects from Gleevec are too difficult to manage?
- If a patient has been on Gleevec for four years and all tests from the beginning have shown a major molecular response but never a complete molecular response, should he or she be looking for an alternative drug treatment?
- Does Gleevec and the newer prescription drugs cross the blood-brain barrier and affect the nerve transmitters and/or cognitive functionality?
- Is it a good idea to have a bone density test performed, as a recent study has linked bone density concerns with taking imatinib?